Revolutionizing Liver Disease Treatment: Resolution Therapeutics Secures $85M in Series B Funding

Resolution Therapeutics is excited to announce that we have successfully raised $85 million in funding to advance our pioneering work in macrophage cell therapy for inflammatory organ diseases, with an initial focus on chronic liver disease. Founded through a synergistic collaboration between Edinburgh’s Centre for Regenerative Medicine, the Scottish National Blood Transfusion Service, and Syncona Investment Management Limited, our company is uniquely positioned at the forefront of biotechnological innovation, nestled within the Centre for Regenerative Medicine on the Edinburgh Royal Infirmary Campus. Chronic liver disease remains a significant global health challenge, impacting millions and being the only chronic disease continuing its upward trajectory in western nations. Presently, patients suffering from this debilitating condition only have access to supportive therapies, and those in the end-stages face the daunting prospect of liver transplantation—an intricate procedure often hampered by complications and a critical shortage of organ donors. Our groundbreaking macrophage cell therapy aims to transform treatment paradigms by targeting patients at risk of liver decompensation, offering them a viable alternative to transplantation and improving their quality of life. This funding will enable us to advance our clinical research, expedite product development, and ultimately bring our innovative therapy to the patients who need it most. With this financial backing, Resolution Therapeutics is poised to make meaningful strides in addressing the needs of those afflicted with chronic liver disease, and we are deeply grateful to our investors for their confidence in our mission and vision.